- To be eligible for enrollment in this study, patients must be prescribed oral Medrol
tablets (4mg and 16 mg) for contact dermatitis as per the locally approved prescribing
information
- Medrol tablets, will be prescribed to the patient by the physician according to
his/her usual practice. The decision to prescribe Medrol tablet will necessarily
precede and will be independent of the decision to enroll patient into the study
- Only those patients, who are ready to sign an informed consent, will be included in
the study
- Subject can be contacted through telephone
- Patients who have any other dermatological or systemic condition that may interfere or
confound with the study outcome measurements
- Patients taking any oral steroid preparation or immunomodulators or have taken any
such oral medication during last 15 days before enrollment. NSAIDs (Non Steroidal
Anti-Inflammatory Agents) are excluded from the list
- Any contraindication to Medrol tablet use. Contraindications of Medrol use are
systemic fungal infections and known hypersensitivity to components
- Participation in other studies within last 1 month before the current study begins
and/or during study participation
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study